{"id": "1adc970c-d433-44d0-aa09-d3834986f7a2", "result": " Contradiction.\n\nThe text states that the event-free survival rate in the exemestane arm was 88% (87 to 89), while the event-free survival rate in the anastrozole arm was 89% (88 to 90). This means that the difference between the two arms was only 1%, not 13.2%."}
{"id": "6b9162d0-0816-46d4-81af-c60028dcc63b", "result": " Contradiction.\n\nThe primary trial excludes patients with cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal), but the secondary trial does not mention any exclusion criteria related to ejection fraction. However, the secondary trial does have an inclusion criterion that patients must be 55 years of age or younger, so patients who are 55 years of age or over would not be eligible for the secondary trial regardless of their ejection fraction."}
{"id": "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f", "result": " Contradiction.\n\nThe primary trial reports 1 case of enterocolitis out of 167 participants (0.60%), while the secondary trial reports 0 cases of enterocolitis out of 458 participants (0.00%). This means that the incidence of enterocolitis was significantly lower in the secondary trial compared to the primary trial."}
{"id": "cc1f712a-2116-4e40-9810-f315e3fa5ff8", "result": " Entailment.\n\nThe text states that the outcome measurement for the primary trial is local control using ipsilateral breast tumor recurrence rates, and that the time frame is 2 years after treatment completion. It does not mention PFS or objective response rate."}
{"id": "904061c0-14fa-4f13-9118-9a41e24fa8eb", "result": " Contradiction.\n\nThe text states that \"Prior treatment with fulvestrant\" and \"Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor\" are both exclusion criteria for the primary trial. This means that patients who have received prior treatment with fulvestrant or a PI3K inhibitor will not be able to participate in the trial."}
{"id": "43ee7645-ce1e-42d5-9a74-3e379f6f367b", "result": " Contradiction.\n\nThe text states that \"HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study).\" This means that patients with HER2-positive status are not excluded from the primary trial."}
{"id": "0cef8c8e-7986-46c7-a597-c5733a9899c0", "result": " Contradiction.\n\nThe text states that the median PFS in cohort 1 of the primary trial was 9.1 months (6.8 to 10.8), while the median PFS in cohort 2 was 7.1 months (5.6 to 10.8). This means that the shortest PFS in cohort 1 was 6.8 months, while the shortest PFS in cohort 2 was 5.6 months."}
{"id": "43ce26e5-03fa-4e9d-b0eb-6ea356295753", "result": " Entailment.\n\nThe text states that \"Cycles 1-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab\" and \"Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off\" for cohort 1 and cohort 2 respectively. This means that both cohorts undergo a total of 17 cycles, each lasting 3 weeks."}
{"id": "3facad41-0221-42f8-834d-470e65c4aad5", "result": " Contradiction.\n\nThe text states that the outcome measurement of the primary trial is \"Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen\". This means that the outcome measurement is not the length of time during and after the treatment that a patient survives with the disease."}
{"id": "9cbc00e9-3a2d-4471-a93e-72c95132fb6a", "result": " Entailment.\n\nThe text states that \"congestive heart failure *1/35 (2.86%)\" in Adverse Events 1 and \"congestive heart failure *0/40 (0.00%)\" in Adverse Events 2. This means that the only case of congestive heart failure in the primary trial occurred in cohort 1."}
{"id": "8b91cab9-d858-45f3-bf8d-3d6fc55b4818", "result": " Entailment.\n\nThe text states that \"The proportion of SNs detected by the Tc method (PTc) is (A + B)/N\" and \"the proportion of SNs detected by the ICG method (PICG) is (A + C)/N\". This means that the primary trial results section reports two different measurements, PTc and PICG."}
{"id": "4a75574c-fa86-4e62-a210-81c7b98a3807", "result": " Contradiction.\n\nThe text states that \"Histologically confirmed stage I, II, or III breast cancer\" and \"T1-3, N0-2, M0\". This means that T4 N2 M4 patients are not eligible for the primary trial."}
{"id": "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 92\". This means that the primary trial results section reports two measurements for one cohort, not for all 3 cohorts."}
{"id": "b0b61978-57db-4a1c-812c-509e8b05f2dc", "result": " Entailment.\n\nThe text states that \"Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\" and \"Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\". This means that both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have."}
{"id": "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1", "result": " Contradiction.\n\nThe text states that \"Inclusion Criteria Phase 1\" and \"Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ\". This means that patients must have a palpable carcinoma to be included in the primary trial."}
{"id": "fbb62216-2cf2-4813-ad41-12a86940610f", "result": " Contradiction.\n\nThe text states that \"Anaemia 7/199 (3.52%)\" in Adverse Events 1 and \"Anaemia 2/36 (5.56%)\" in Adverse Events 2. This means that Anaemia was not the most common adverse event in cohort 1 and 2 of the primary trial."}
{"id": "961a956e-fece-4baa-a2ad-d3a5320bd9d2", "result": " Contradiction.\n\nThe text states that \"Median (95% Confidence Interval) 8.4 (7.0 to 9.9)\". This means that the shortest PFS in cohort 1 of the primary trial was 7.0 months, not less than 3 weeks."}
{"id": "97fd111c-6969-43ab-93af-b3dff09960e5", "result": " Contradiction.\n\nThe text states that \"Total: 0/0\". This means that the adverse events section in the primary trial does not report the incidence rate of any AEs."}
{"id": "eb1bfb08-eba0-4130-b328-00f56c0f84a6", "result": " Contradiction.\n\nThe text states that \"Diarrhoea 5/65 (7.69%)\" in the primary trial and \"Anaemia 6/472 (1.27%)\" in the secondary trial. This means that Diarrhoea is not the most common adverse event in the primary trial and the secondary trial."}
{"id": "b1219e71-fbf5-4bba-8a93-a27ae444e3e1", "result": " Entailment.\n\nThe text states that \"Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\" and \"Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed)\". This means that to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer."}
{"id": "f10f3b84-e039-4a02-a98b-86d149d9a16f", "result": " Entailment.\n\nThe text states that \"Being treated with flucytosine\". This means that ongoing flucytosine treatments are not permitted for participants of the primary trial."}
{"id": "0ddb07ae-6e70-436d-8723-f609e59c57da", "result": " Contradiction.\n\nThe text states that \"Study drug 190 mg/m^2 for 2 to 4 weeks\". This means that the primary trial participants recieve doses of Pralatrexate that are not calculated based on bodyweight."}
{"id": "c10eea1a-5768-442d-ae07-20b4f8f4b583", "result": " Contradiction.\n\nThe text states that \"HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies\". This means that only patients with HER-2 positive breast cancer are eligible for the primary trial."}
{"id": "2ef186d0-b4ab-44de-b785-a63e9e95851a", "result": " Entailment.\n\nThe text states that \"Enterocolitis 0/167 (0.00%)\" in the primary trial and \"Enterocolitis 0/458 (0.00%)\" in the secondary trial. This means that most participants in the secondary trial and the primary trial did not suffer from Enterocolitis."}
{"id": "fef5aedb-21c0-4130-b8a3-cb1df5017c7a", "result": " Entailment.\n\nThe text states that \"Total: 0/0\". This means that the adverse events section in the primary trial is empty."}
{"id": "2655c892-216e-4b96-a8f2-6f64403215c5", "result": " Entailment.\n\nThe text states that \"Thrombocytopenia * 0/65 (0.00%)\", \"Anaemia * 20/65 (0.00%)\", \"Febrile neutropenia * 20/65 (0.00%)\", and \"Leukopenia * 20/65 (0.00%)\" in Adverse Events 1. This means that there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial."}
{"id": "2825d63b-8f22-4fb8-829f-9567845251c6", "result": " Contradiction.\n\nThe text states that \"Age 18 years\". This means that adults can take part in the primary trial."}
{"id": "6b35bc10-f591-4b84-abac-40a74be949fa", "result": " Entailment.\n\nThe text states that \"Prior treatment with fulvestrant\" and \"Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor\". This means that prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial."}
{"id": "a5baab2c-9c32-4301-a574-4ba5a0c2eb00", "result": " Contradiction.\n\nThe text states that \"Presence of hot flashes for 30 days prior to study registration\" in the primary trial and does not mention any such requirement for the secondary trial. This means that presence of hot flashes for at least 4 month prior to study registration is not required for all patients that want to participate in the primary trial or the secondary trial."}
{"id": "70677d5f-7022-404c-8410-d1f89366d92f", "result": " Contradiction.\n\nThe text states that \"Number of Patients With Pathological Complete Response Rate\" in the primary trial and \"Disease Free Survival\" in the secondary trial. This means that the secondary trial and the primary trial do not both measure the pCR and tumor diameter of their patient cohorts."}
{"id": "f46a7d27-a94f-4389-a1a0-4a8f5177b354", "result": " Contradiction.\n\nThe text states that \"Anaemia * 4/100 (4.00%)\" in Adverse Events 1. This means that Anemia affects more than one patient in the primary trial."}
{"id": "fe876bb0-7ce3-4197-81ad-920f1f77938e", "result": " Entailment.\n\nThe text states that \"88 (87 to 89)\" in Results 1 and \"89 (88 to 90)\" in Results 2. This means that there is a minimal difference between the results from the two the primary trial cohorts."}
{"id": "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929", "result": " Contradiction.\n\nThe text states that \"Age between 18 years and 70 years\" and \"Karnofsky performance status index > 80 %\". This means that to be eligible for the primary trial candidates must be over the age of 18 and have a Karnofsky performance status index > 80 %, but does not mention any requirement for having a severe disability."}
{"id": "4f705481-5dd0-414c-b375-c56e8c235b42", "result": " Entailment.\n\nThe text states that \"Skin infection 2/41 (4.88%)\". This means that the most common adverse event in the primary trial was skin infection."}
{"id": "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2", "result": " Contradiction.\n\nThe text states that \"Febrile Neutropenia * 3/56 (5.36%)\". This means that Febrile Neutropenia was not the most common adverse event recorded in the primary trial, and did not affect most patients in the trial."}
{"id": "c09fa61c-967a-40ae-96b0-c87b7cde237b", "result": " Entailment.\n\nThe text states that \"Anaemia * 4/100 (4.00%)\", \"Febrile neutropenia * 3/100 (3.00%)\", \"Neutropenia * 1/100 (1.00%)\", \"Pancytopenia * 0/100 (0.00%)\", \"Thrombocytopenia * 1/100 (1.00%)\", \"Acute coronary syndrome * 1/100 (1.00%)\", \"Stress cardiomyopathy * 0/100 (0.00%)\", \"Abdominal pain * 0/100 (0.00%)\", \"Abdominal pain upper * 0/100 (0.00%)\", \"Ascites * 1/100 (1.00%)\", \"Anaemia * 0/152 (0.00%)\", \"Febrile neutropenia * 3/152 (1.97%)\", \"Neutropenia * 1/152 (0.66%)\", \"Pancytopenia * 1/152 (0.66%)\", \"Thrombocytopenia * 0/152 (0.00%)\", \"Acute coronary syndrome * 0/152 (0.00%)\", \"Stress cardiomyopathy * 1/152 (0.66%)\", \"Abdominal pain * 2/152 (1.32%)\", \"Abdominal pain upper * 2/152 (1.32%)\", and \"Ascites * 0/152 (0.00%)\". This means that none of the individual AEs recorded in the primary trial affect more than 10% of the population."}
{"id": "4309860d-042d-45a4-8a0a-a9fdd075247a", "result": " Contradiction.\n\nThe text states that \"In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle\". This means that Cohort 1 receives NKTR-102 by infusion."}
{"id": "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85", "result": " Contradiction.\n\nThe text states that \"Number of participants experiencing CR, PR or SD as defined by Response Evaluation Criteria In Solid Tumors (RECIST)\" in the primary trial and \"Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants)\" in the secondary trial. This means that the primary trial and the secondary trial do not use identical outcome measurements."}
{"id": "59cd7909-00c3-4c23-9a08-a42dbc8eabdd", "result": " Entailment.\n\nThe text states that \"Each treatment cycle is 28 days. Participants will be treated until disease progression\". This means that participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression."}
{"id": "e6a4e9a6-56b8-4a30-9743-eb02688c090f", "result": " Entailment.\n\nThe text states that \"Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria\" and \"Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics: node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR node-negative AND at least one of the following features: Tumor >2 cm or Tumor >1 cm and Negative estrogen receptor/progesterone receptor (ER/PR) or Malignancy Grade 2-3 or Presence of peritumoral vascular invasion or Age <35 years\". This means that a patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm."}
{"id": "82a3e542-f784-44d7-90f6-34d7e969283c", "result": " Entailment.\n\nThe text states that \"All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking\". This means that the primary trial participants receive more than one type of medication during the study."}
{"id": "fb360514-14be-45ab-8b74-ea5a7eb181d7", "result": " Contradiction.\n\nThe text states that \"Total: 0/23 (0.00%)\" in Primary Trial Adverse Events 1 and \"Total: 0/655 (0.00%)\" and \"Total: 0/580 (0.00%)\" in Secondary Trial Adverse Events 1 and 2. This means that the primary trial and the secondary trial report adverse events."}
{"id": "7137dec6-5c98-4156-8035-7bbaaf0b649d", "result": " Contradiction.\n\nThe text states that \"Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\" in the inclusion criteria. This means that ECOG score < 2 is not necessary to be eligible for the primary trial."}
{"id": "015dd869-db90-45a9-a951-9dc7dc2b2e01", "result": " Contradiction.\n\nThe text states that \"Cancer that has spread to the brain\" in the exclusion criteria. This means that patients with a Malignant brain tumour are not eligible for the primary trial. Also, the text states that \"Treatment for another cancer within the last 5 years\" in the exclusion criteria. This means that patients with colon cancer diagnosis are not eligible for the primary trial."}
{"id": "3a4003f6-ff1c-43d8-be48-f767266b2cf5", "result": " Entailment.\n\nThe text states that \"Signed Informed Consent ErbB2(HER2)overexpressing breast cancer. Brain lesion(s) which are progressing. Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. Able to swallow an oral medication. Adequate kidney and liver function. Adequate bone marrow function\" in the secondary trial inclusion criteria and \"Life expectancy < 3 months. Prior severe allergic reaction to paclitaxel therapy. Presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention (NCI CTC Grade 2, 3 or 4). Completion of previous chemotherapy regimen < 3 weeks prior to the start of study treatment. Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy (eg, bevacizumab, trastuzumab) for the treatment of metastatic disease must be discontinued > or = to 3 weeks from the start of protocol treatment. Concurrent medical condition which may increase the risk of toxicity. Patients may not have any clinically significant cardiovascular disease including the following: myocardial infarction or ventricular tachyarrhythmia within 6 months prolonged QTc >480 msec (Fridericia correction) ejection fraction less than institutional normal major conduction abnormality (unless a cardiac pacemaker is present) Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation. The patient may be referred to a cardiologist at the discretion of the principal investigator. Patients with underlying cardiopulmonary dysfunction should be excluded from the study. Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration History of significant bleeding disorder unrelated to cancer, including: Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) Diagnosed acquired bleeding disorder within one year (e.g., acquired antifactor VIII antibodies) Ongoing or recent ( 3 months) significant gastrointestinal bleeding Other medical condition which in the opinion of the Investigator might confer an unacceptable increase in risk. Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake. Presence of uncontrolled gastrointestinal malabsorption syndrome. Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial. Concurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might allowed for pre-existing non-target lesions with approval from the principal investigator of the trial. Patients with > Grade 1 neuropathy will be excluded form this trial\" in the primary trial exclusion criteria. This means that the secondary trial and the primary trial do not have the same inclusion and exclusion conditions."}
{"id": "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7", "result": " Contradiction.\n\nThe text states that \"Median (95% Confidence Interval) Unit of Measure: months 9.1 (6.8 to 10.8)\" in Results 1 and \"Median (95% Confidence Interval) Unit of Measure: months 7.1 (5.6 to 10.8)\" in Results 2. This means that at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of less than 10.8 months."}
{"id": "f3cb9150-32c6-4877-9a87-4fac45a24948", "result": " Entailment.\n\nThe text states that \"Musculoskeletal * 1/62 (1.61%)\" in the secondary trial adverse events 1 and \"Musculoskeletal * 0/64 (0.00%)\" in the secondary trial adverse events 2 and \"Total: 0/34 (0.00%)\" in the primary trial adverse events 1. This means that between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial."}
{"id": "9d8b26d6-d574-4717-88b6-77458bc683f3", "result": " Contradiction.\n\nThe text states that \"Total: 5/55 (9.09%) Infection 2/55 (3.64%) Pain * 1/55 (1.82%) Muscle Weakness * 1/55 (1.82%) Dyspnea 1/55 (1.82%)\" in the primary trial adverse events 1. This means that Syncope was not the most common adverse event recorded in the primary trial."}
{"id": "51be7c95-8da4-419c-950c-91ebdd2c3fe5", "result": " Contradiction.\n\nThe text does not provide any information about the doses of BKM120 received by patients in the primary trial or the secondary trial. Therefore, it is not possible to determine whether all patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial."}
{"id": "07042b0f-d422-49c3-8d53-81319927a4b3", "result": " Contradiction.\n\nThe text states that \"Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition\" in the primary trial eligibility inclusion criteria and \"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Patients with metastatic or advanced solid tumors Women with histologically or cytologically confirmed triple negative breast carcinoma Participants with histologically or cytologically confirmed pancreatic adenocarcinoma Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)\" in the secondary trial eligibility inclusion criteria. This means that all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is a specific stage of cancer required for entry to the secondary trial."}
{"id": "32361e21-ee57-4c34-9390-833ba5048a10", "result": " Contradiction.\n\nThe text states that \"Fulvestrant was administered intramuscularly (in the gluteus maximus)\" in the primary trial intervention. This means that the primary trial participants are administered Fulvestrant intramuscularly (to the gluteus maximus) and Everolimus orally."}
{"id": "88668508-dfd4-4a39-91cd-cf1654a6dfc4", "result": " Contradiction.\n\nThe text states that \"Outcome Measurement: Local Control Using Ipsilateral Breast Tumor Recurrence Rates\" in the primary trial results. This means that the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience ipsilateral breast tumor recurrence rates."}
{"id": "dca4c9f7-bb2a-4f73-b390-93b7ced87c73", "result": " Entailment.\n\nThe text states that \"Outcome Measurement: Number of Participants With Complete Pathologic Response\" in the primary trial results and \"Outcome Measurement: Change in Masood Score\" in the secondary trial results. This means that the results from the secondary trial and the primary trial are non-comparable."}
{"id": "e7604382-09cd-43b4-998f-a51b33f25c5a", "result": " Contradiction.\n\nThe text states that \"Patients receive cetuximab IV over 60-120 minutes once a week\" in the secondary trial intervention and \"Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD)\" in the primary trial intervention. This means that the primary trial and the secondary trial participants do not receive any medication orally."}
{"id": "75affd49-4905-4d43-9a5c-ef795281bac4", "result": " Entailment.\n\nThe text states that \"Arm A -Liposomal Doxorubicin Then Docetaxel\" in the primary trial results 1 has 28 (16 to 42) percentage of patients and \"Arm B - Docetaxel Then Liposomal Doxorubicin\" in the primary trial results 2 has 31 (18 to 45) percentage of patients. This means that neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients."}
{"id": "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65", "result": " Contradiction.\n\nThe text states that \"Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\" in the primary trial eligibility inclusion criteria and \"Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).\" This means that to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have not received prior chemotherapy for this cancer."}
{"id": "8c6314f7-34f5-42a7-ba66-b95d050a6315", "result": " Contradiction.\n\nThe text states that \"Median (95% Confidence Interval) 8.4 (7.0 to 9.9)\" in the primary trial results 1 and \"Median (95% Confidence Interval) 8.5 (6.9 to 11.5)\" in the primary trial results 2. This means that the shortest PFS in cohort 1 of the primary trial was not 1.4 months below average."}
{"id": "f114846e-79d8-4712-add0-bb34b65d418f", "result": " Contradiction.\n\nThe text states that \"Outcome Measurement: Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)\" in the primary trial results. This means that there were not 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2."}
{"id": "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe", "result": " Contradiction.\n\nThe text states that \"The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment\" in the primary trial results. This means that the primary trial reports the changes in the size of lesions for patients in its cohorts."}
{"id": "b1d28450-fc7d-496a-9c7c-bf711b28f8e4", "result": " Contradiction.\n\nThe text states that \"Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization\" in the primary trial eligibility inclusion criteria and \"Pregnant,\" in the primary trial eligibility exclusion criteria. This means that all pregnant patients accepted into the primary trial have not undergone Prior treatment for breast cancer with endocrine therapy."}
{"id": "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3", "result": " Entailment.\n\nThe text states that \"Total: 2/30 (6.67%) Dry Eyes [1]1/30 (3.33%) Diarrhea [2]1/30 (3.33%)\" in the primary trial adverse events. This means that no cardiac or neural adverse events were recorded in the primary trial."}
{"id": "a805f174-2707-4302-a195-05153ea8523e", "result": " Entailment.\n\nThe text states that \"Age 18 years\" in the primary trial eligibility inclusion criteria. This means that only adults can take part in the primary trial."}
{"id": "e4aeb013-7713-4b73-acbd-f8379cc6a494", "result": " Contradiction.\n\nThe text states that \"Total: 5/101 (4.95%) SLIPPED DISK * 0/101 (0.00%)\" in the primary trial adverse events 1 and \"Total: 9/98 (9.18%) SLIPPED DISK * 1/98 (1.02%)\" in the primary trial adverse events 2. This means that there was a higher percentage of patients with slipped disks in cohort 1 of the primary trial than in cohort 2."}
{"id": "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3", "result": " Contradiction.\n\nThe text states that \"Mean (95% Confidence Interval) 8.8 (7.8 to 9.8)\" in the primary trial results 1. This means that not all patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months."}
{"id": "2729a321-709b-4392-9604-dd7237bedb17", "result": " Entailment.\n\nThe text states that \"percentage of patients 80.1 (78.0 to 82.0)\" in the primary trial results 1 and \"percentage of patients 82.2 (80.2 to 84.0)\" in the primary trial results 2. This means that the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years."}
{"id": "8e9611fc-89f8-44cb-af09-8d71a13ca082", "result": " Entailment.\n\nThe text states that \"In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle\" in the primary trial intervention 1 and \"In Group B, TPC will be administered per standard of care\" in the primary trial intervention 2. This means that cohort 1 and 2 of the primary trial do not receive the same intervention."}
{"id": "b9491012-49ba-4eb1-8230-1966f54ea012", "result": " Entailment.\n\nThe text states that \"Extracranial metastases allowed\" in the primary trial eligibility disease characteristics. This means that patients with Extracranial metastases can be eligible for the primary trial."}
{"id": "62e449ad-16b3-479d-94a5-ffc435b5e99c", "result": " Entailment.\n\nThe text states that \"Cancer that has spread to the brain\" in the primary trial exclusion criteria. This means that patients with a Malignant brain tumour diagnosis are excluded from the primary trial."}
{"id": "565d7982-aa9a-4c01-987c-1d67bc9c212d", "result": " Contradiction.\n\nThe text states that \"Being treated with flucytosine\" in the primary trial exclusion criteria. This means that ongoing flucytosine treatments are not necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry."}
{"id": "7271e0db-bb82-423f-ad95-5ffa84fab97e", "result": " Contradiction.\n\nThe text states that \"Total: 3/12 (25.00%) Urosepsis 2/12 (16.67%)\" in the primary trial adverse events and \"Total: 18/65 (27.69%) Anaemia 5/65 (7.69%) Febrile neutropenia 1/65 (1.54%) Leukocytosis 0/65 (0.00%) Neutropenia 4/65 (6.15%) Thrombocytopenia 6/65 (9.23%) Cardiac failure congestive 0/65 (0.00%) Epigastric discomfort 0/65 (0.00%) Nausea 1/65 (1.54%) Vomiting 3/65 (4.62%) Condition aggravated 0/65 (0.00%) Medical device complication 0/65 (0.00%)\" in the secondary trial adverse events 1 and \"Total: 22/66 (33.33%) Anaemia 1/66 (1.52%) Febrile neutropenia 2/66 (3.03%) Leukocytosis 1/66 (1.52%) Neutropenia 2/66 (3.03%) Thrombocytopenia 0/66 (0.00%) Cardiac failure congestive 1/66 (1.52%) Epigastric discomfort 1/66 (1.52%) Nausea 0/66 (0.00%) Vomiting 1/66 (1.52%) Condition aggravated 1/66 (1.52%) Medical device complication 1/66 (1.52%)\" in the secondary trial adverse events 2. This means that there are more cases of Urosepsis in the primary trial than in the secondary trial."}
{"id": "6402e13a-7cfb-4774-b7f9-80ecb79fda2a", "result": " Contradiction.\n\nThe text states that \"Patients receive oral exemestane (25 mg) once daily for 5 years\" in the secondary trial intervention 1 and \"Patients receive oral anastrozole (1 mg) once daily for 5 years\" in the secondary trial intervention 2. This means that the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally."}
{"id": "734423d5-4b47-4448-ab98-811015d626f0", "result": " Entailment.\n\nThe text states that \"Total: 3/39 (7.69%) Neutropenia 1/39 (2.56%)\" in the primary trial adverse events 1 and \"Total: 3/21 (14.29%) Neutropenia 1/21 (4.76%)\" in the primary trial adverse events 2. This means that there were multiple patients which suffered Neutropenia in both cohorts of the primary trial."}
{"id": "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd", "result": " Contradiction.\n\nThe text states that \"Arm A - Flaxseed & Active Anastrazole 25 mg flaxseed per day and 1 mg anastrozole pill per day Anastrozole: 1 mg per day\" in the primary trial intervention 1. This means that all the primary trial participants are administered Anastrazole in a pill form. However, the text also states that \"Phase 1 - Cohort A Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer Anastrozole AZD0530\" in the secondary trial intervention 1. This means that none of the secondary trial receive any Anastrazole."}
{"id": "32ed503c-1cfd-44f6-b8bb-23d9d175d73d", "result": " Entailment.\n\nThe text states that \"Able to lie still for 1.5 hours for PET scanning\" in the primary trial eligibility inclusion criteria. This means that patients must be able to undergo a PET scan to participate in the primary trial."}
{"id": "175044aa-72b1-405d-8506-30002f5098e4", "result": " Contradiction.\n\nThe text states that \"Total: 0\" in the primary trial adverse events 1. This means that there is no information about the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study."}
{"id": "045ad91e-44fa-42cc-ac22-a7aab26a9009", "result": " Contradiction.\n\nThe text states that \"All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking\" in the primary trial intervention 1. This means that the primary trial participants are administered Avastin, Bevacizumab and hormonal therapy as part of the intervention."}
{"id": "00822101-fa21-4a26-bf45-3b1f535da005", "result": " Entailment.\n\nThe text states that \"HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study)\" in the primary trial eligibility exclusion criteria. This means that a patient with a HER2-positive status can not take part in the primary trial."}
{"id": "06f798d1-2956-4903-83e9-58a41fa425f7", "result": " Entailment.\n\nThe text states that \"Total: 0/655 (0.00%)\" in the primary trial adverse events 1, \"Total: 0/580 (0.00%)\" in the primary trial adverse events 2, \"Total: 0/15 (0.00%)\" in the secondary trial adverse events 1, and \"Total: 0/16 (0.00%)\" in the secondary trial adverse events 2. This means that the primary trial and the secondary trial do not record any cardiac or infection related adverse events."}
{"id": "8648c7df-582a-42a9-9330-414b2430ac56", "result": " Contradiction.\n\nThe text states that \"Total: 340/1612 (21.09%)\" in the primary trial adverse events 1 and \"Total: 350/1623 (21.57%)\" in the primary trial adverse events 2. This means that in total more than 100 patients suffer adverse events."}
{"id": "89f610a7-9e81-43a4-8c1e-5503233b2be1", "result": " Contradiction.\n\nThe text states that \"Pathologically confirmed diagnosis of breast cancer with documented progressive disease\" in the primary trial eligibility inclusion criteria. This means that breast cancer patients must have documented progressive disease to participate in the primary trial."}
{"id": "b0046821-ba27-4a90-8869-cb708b843aa4", "result": " Contradiction.\n\nThe text states that \"Arm A - Flaxseed & Active Anastrazole 25 mg flaxseed per day and 1 mg anastrozole pill per day flaxseed: 25 g per day ground Arm B - Flaxseed Flaxseed 25 mg per day and 1 placebo pill per day flaxseed: 25 g per day ground\" in the primary trial intervention 1 and 2. This means that all the primary trial participants are administered flaxseed. However, the text also states that \"Phase 1 - Cohort A Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer Anastrozole AZD0530\" in the secondary trial intervention 1. This means that none of the secondary trial receive any flaxseed."}
{"id": "d1b217ae-76f3-4ba6-958e-5b2558703ba4", "result": " Entailment.\n\nThe text states that \"Total: 1/35 (2.86%) congestive heart failure *1/35 (2.86%)\" in the primary trial adverse events 1 and \"Total: 0/40 (0.00%) congestive heart failure *0/40 (0.00%)\" in the primary trial adverse events 2. This means that several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2."}
{"id": "8ddf8b88-6e06-4c71-9e28-45f73a637af0", "result": " Contradiction.\n\nThe text states that \"Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm)\" in the primary trial intervention 1. This means that the primary trial participants are administered topical medication. However, the text also states that \"Patients receive oral exemestane (25 mg) once daily for 5 years\" in the secondary trial intervention 1 and \"Patients receive oral anastrozole (1 mg) once daily for 5 years\" in the secondary trial intervention 2. This means that the secondary trial patients only receive treatment orally."}
{"id": "0ea29bd5-20be-40ea-8ad7-705d283d1d48", "result": " Contradiction.\n\nThe text states that \"Measure Type: Number Unit of Measure: percentage of patients 80.1 (78.0 to 82.0)\" in the primary trial results 1 and \"Measure Type: Number Unit of Measure: percentage of patients 82.2 (80.2 to 84.0)\" in the primary trial results 2. This means that the majority of participants in cohort 1 and 2 of the primary trial did not suffer any kind of Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer."}
{"id": "e147796d-2edd-42d1-ac53-300fb8bd5eb6", "result": " Contradiction.\n\nThe text states that \"Participants received lapatinib 1500 milligrams (mg) orally once daily\" in the primary trial intervention 1 and \"Participants received matching placebo orally once daily\" in the primary trial intervention 2. This means that 80% of patients in the primary trial received lapatinib, but not a placebo."}
{"id": "6b33b4ae-36f2-4a53-a954-6f246f6e023d", "result": " Entailment.\n\nThe text states that \"Known and documented HER2-positive Known and documented LVEF of at least 50 percent (%)\" in the primary trial eligibility inclusion criteria. This means that patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)."}
{"id": "06fad978-1dc3-46f5-b45f-5ac6577f28b9", "result": " Contradiction.\n\nThe text states that \"Females with histologic or cytologic diagnosis of advanced breast cancer\" in the primary trial eligibility inclusion criteria. This means that patients must be female and have confirmed advanced breast cancer to be eligible for the primary trial. However, the text also states that \"Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\" in the secondary trial eligibility inclusion criteria. This means that patients must be female and have confirmed advanced breast cancer and be postmenopausal women to be eligible for the secondary trial."}
{"id": "878c09e7-3fd9-404e-921e-5b549e9578fb", "result": " Entailment.\n\nThe text states that \"Overall Number of Participants Analyzed: 70 Measure Type: Count of Participants Unit of Measure: Participants Grade 1: 53 75.7% Grade 2: 40 57.1% Grade 3: 18 25.7% Grade 4: 2 2.9% Grade 5: 12 17.1%\" in the primary trial results 1. This means that most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4."}
{"id": "3a0c517d-9b9a-4497-9675-50ff12cd02b7", "result": " Contradiction.\n\nThe text states that \"Cardiac failure * 2/219 (0.91%) Left ventricular dysfunction * 2/219 (0.91%) Abdominal pain * 1/219 (0.46%) Abdominal pain upper * 1/219 (0.46%)\" in the primary trial adverse events 1. This means that in cohort 1 of the primary trial there were more cases of Abdominal pain than Left ventricular dysfunction."}
{"id": "9abb10d7-496e-44fd-915d-d86aedf6c9b6", "result": " Contradiction.\n\nThe text states that \"Known and documented HER2-positive Known and documented LVEF of at least 50 percent (%)\" in the primary trial eligibility inclusion criteria. This means that patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)."}
{"id": "8460a212-8054-4bd2-b4e6-af1d137a2f79", "result": " Entailment.\n\nThe text states that \"Measure Type: Number Unit of Measure: percentage of participants 26 (13 to 44)\" in the primary trial results 1 and \"Measure Type: Number Unit of Measure: proportion of nodes Proportion of SNs (PTc) detected by Tc method: 0.86 Proportion of SNs (PICG) detected by ICG method: 0.95\" in the secondary trial results 1. This means that the primary trial and the secondary trial report their results using different units of measure."}
{"id": "a3390ae6-d41d-4dc7-899e-de9534adfd6b", "result": " Contradiction.\n\nThe text states that \"Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle\" in the primary trial intervention 1. This means that the primary trial participants receive the same doses of Capecitabine as of Lapatinib."}
{"id": "17bbea92-8f92-41f3-9b9d-cf6e62cf6798", "result": " Contradiction.\n\nThe text states that \"Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m\u00b2 IV on days 1, 8, and 15 of a 28 day cycle\" in the primary trial outcome measurement. This means that the primary trial reports the incidence of dose limiting toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m\u00b2 IV on days 1, 8, and 15 of a 28 day cycle."}
{"id": "794269ca-e7ec-4a65-ace5-b0f24a8cdc15", "result": " Entailment.\n\nThe text states that \"Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])\" in the primary trial results and \"Outcome Measurement: Progression Free Survival PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause\" in the secondary trial results. This means that the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS."}
{"id": "4dfff980-6a2b-4f01-9194-6ec831d6fed7", "result": " Entailment.\n\nThe text states that \"Total: 5/55 (9.09%) Infection 2/55 (3.64%)\" in the primary trial adverse events 1. This means that Infections were the most common adverse events recorded in the primary trial."}
{"id": "dc4c57b0-8c75-494e-81b0-3528df85ebff", "result": " Contradiction.\n\nThe text states that \"Outcome Measurement: Overall Survival (OS) of Patients\" in the secondary trial results. This means that the secondary trial records the Overall Survival (OS) of Patients in its cohorts."}
{"id": "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c", "result": " Contradiction.\n\nThe text states that \"An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST\" in the primary trial results and \"OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST)\" in the secondary trial results. This means that the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response."}
{"id": "251a20d8-2555-4929-9d01-c02311bdc93f", "result": " Entailment.\n\nThe text states that \"Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: participants 35\" in the primary trial results 1 and \"Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants 40\" in the primary trial results 2. This means that a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1."}
{"id": "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1", "result": " Entailment.\n\nThe text states that \"Outcome Measurement: LDex Change- Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases\" in the primary trial results and \"Outcome Measurement: Overall Survival (OS) of Patients To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC)\" in the secondary trial results. This means that the secondary trial and the primary trial do not record the same metrics in their results section."}
{"id": "f0273b8c-460d-46fe-9c52-8ff4b08e439b", "result": " Contradiction.\n\nThe text states that \"women >=18 years of age\" in the primary trial eligibility inclusion criteria. This means that eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial."}
{"id": "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8", "result": " Entailment.\n\nThe text states that \"Pathologically confirmed diagnosis of breast cancer with documented progressive disease\" in the primary trial eligibility inclusion criteria. This means that Breast cancer patients must have documented progressive disease to participate in the primary trial."}
{"id": "c2217d42-e90c-4ffe-b084-e653b9ace4d5", "result": " Contradiction.\n\nThe text states that \"Total: 0/655 (0.00%)\" in the primary trial adverse events 1 and \"Total: 0/580 (0.00%)\" in the primary trial adverse events 2. This means that the primary trial and the secondary trial do not record any cardiac or infection related adverse events."}
{"id": "080da381-b5dd-46d3-99c4-18112da153c1", "result": " Contradiction.\n\nThe text states that \"Acute myocardial infarction 0/199 (0.00%) Cardiopulmonary failure 1/199 (0.50%) Supraventricular tachycardia 0/199 (0.00%)\" in the secondary trial adverse events 1 and \"Acute myocardial infarction 1/36 (2.78%) Cardiopulmonary failure 0/36 (0.00%) Supraventricular tachycardia 1/36 (2.78%)\" in the secondary trial adverse events 2. This means that There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial."}
{"id": "c100a7cd-e3a2-4901-a3e0-12336f769c7b", "result": " Contradiction.\n\nThe text states that \"Conjunctivitis 0/519 (0.00%)\" in the secondary trial adverse events 1 and \"Conjunctivitis 1/48 (2.08%)\" in the primary trial adverse events 1. This means that the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16."}
{"id": "ec1e269e-470d-43d9-8f23-8a19a5c96fcc", "result": " Contradiction.\n\nThe text states that \"Anaemia 7/199 (3.52%)\" in the primary trial adverse events 1 and \"Anaemia 2/36 (5.56%)\" in the primary trial adverse events 2. This means that Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2."}
{"id": "21611c2a-e6eb-4012-a209-9b6781e1f260", "result": " Contradiction.\n\nThe text states that \"Total: 0\" in the primary trial adverse events 1. This means that There is an adverse events section in the primary trial."}
{"id": "d1b7105d-0b7d-4b10-92a7-d63243ff0629", "result": " Contradiction.\n\nThe text states that \"Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal)\" in the primary trial eligibility exclusion criteria and \"Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months)\" in the secondary trial eligibility inclusion criteria. This means that Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger."}
{"id": "7f3fe97e-68ee-470f-b06e-21cdddb67aa8", "result": " Contradiction.\n\nThe text states that \"Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition\" in the primary trial eligibility inclusion criteria and \"Patients with metastatic or advanced solid tumors\" in the secondary trial eligibility inclusion criteria. This means that all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial."}
{"id": "ce8464bd-951e-44aa-97d9-10b917b055ce", "result": " Contradiction.\n\nThe text states that \"SLIPPED DISK * 0/101 (0.00%)\" in the primary trial adverse events 1 and \"SLIPPED DISK * 1/98 (1.02%)\" in the primary trial adverse events 2. This means that there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1."}
{"id": "0131ebe3-746b-45a5-ba60-fdd326974fec", "result": " Entailment.\n\nThe text states that \"Outcome Measurement: Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants\" in the primary trial results and \"Outcome Measurement: Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants)\" in the secondary trial results. This means that the primary trial and the secondary trial use comparable outcome measurements."}
{"id": "b1dd7632-ed92-40a9-9293-bce68619c658", "result": " Contradiction.\n\nThe text states that \"Newly diagnosed with stage I-III cancer of the female breast\" in the primary trial eligibility criteria. This means that Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible."}
{"id": "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc", "result": " Entailment.\n\nThe text states that \"Fulvestrant was administered intramuscularly (in the gluteus maximus)\" and \"Everolimus was administered initially at a dose of 5 mg daily\" in the primary trial intervention. This means that the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally."}
{"id": "4a15ec5e-4904-4f01-a0a2-c51e83c8c070", "result": " Entailment.\n\nThe text states that \"Arm/Group Title: Curcumin C3 Complex\" and \"Arm/Group Title: Placebo\" in the primary trial results. This means that the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort."}
{"id": "b9e29ea8-6847-40d4-b5c3-81c496101695", "result": " Contradiction.\n\nThe text states that \"Mean (95% Confidence Interval) 8.8 (7.8 to 9.8)\" in the primary trial results 1. This means that All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months."}
{"id": "2a2c16a7-f427-4fdb-8153-94aac304e4b8", "result": " Contradiction.\n\nThe text states that \"Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.\nCycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.\nCycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.\nCycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.\" in the primary trial intervention 1 and \"Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.\nCycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.\nCycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.\" in the primary trial intervention 2. This means that Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles."}
{"id": "618a3ae1-b22c-4c35-86a6-190c1b5b5d21", "result": " Entailment.\n\nThe text states that \"Life expectancy 1 year\" in the primary trial eligibility inclusion criteria. This means that Patients must have a Life expectancy of at least 1 year to enroll in the primary trial."}
{"id": "e62f5a3f-0091-4980-9822-db8f4dc2502a", "result": " Contradiction.\n\nThe text states that \"Mean (Standard Deviation) 2.6 (0.994)\" in the primary trial results 1 and \"Mean (Standard Deviation) 3.4 (0.554)\" in the primary trial results 2. This means that the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is a difference in the results from these two cohorts."}
{"id": "4a41ac73-538a-43e5-b7ce-8c8e2d56286e", "result": " Contradiction.\n\nThe text states that \"Currently pregnant, or planning to become pregnant during the study period\" and \"Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously\" in the primary trial exclusion criteria and \"Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy)\" in the secondary trial exclusion criteria. This means that Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving neoadjuvant therapy."}
{"id": "75a65913-5655-4377-b441-ecdd4dd75175", "result": " Entailment.\n\nThe text states that \"Newly diagnosed with stage I-III cancer of the female breast\" in the primary trial eligibility criteria. This means that Patients with stage 4 cancer are excluded from the primary trial."}
{"id": "1329dec6-fb2c-4219-9db6-3fef9d94b316", "result": " Contradiction.\n\nThe text states that \"Left ventricular dysfunction * 2/219 (0.91%)\" and \"Abdominal pain * 1/219 (0.46%)\" in the primary trial adverse events 1. This means that in cohort 1 of the primary trial there were 1 less case of Left ventricular dysfunction than Abdominal pain."}
{"id": "29b2fa29-5a76-4877-95bb-1a8de7973d33", "result": " Entailment.\n\nThe text states that \"Total: 6\" in the primary trial adverse events 1. This means that Only 6/67 patients in cohort 1 of the primary trial suffered adverse events."}
{"id": "7edba90d-076d-4f55-b9d6-a1765ceb48bd", "result": " Contradiction.\n\nThe text states that \"Patients receive cetuximab IV over 60-120 minutes once a week.\" in the secondary trial intervention 1. This means that the primary trial and the secondary trial participants receive medication by IV."}
{"id": "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37", "result": " Contradiction.\n\nThe text does not provide information about herceptin."}
{"id": "1314146f-2869-4525-8034-7f732d238385", "result": " Entailment.\n\nThe text states that \"Total: 340/1612 (21.09%)\" and \"Total: 350/1623 (21.57%)\" in the primary trial adverse events 1 and 2. This means that none of the individual adverse events in the primary trial affect more than 100 patients."}
{"id": "7c7418d2-32d7-4517-874b-eb3db24ea16a", "result": " Entailment.\n\nThe text states that \"Age between 18 years and 70 years.\", \"Karnofsky performance status index > 80 %.\", \"Adequate hepatic, renal and heart functions.\", \"Adequate hematology levels.\" in the primary trial eligibility criteria. This means that to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels."}
{"id": "1f6a14ae-e22b-4b40-b389-217570dbf38e", "result": " Entailment.\n\nThe text states that \"Overall Number of Participants Analyzed: 2\" and \"Total: 1\" in the primary trial results 2. This means that 50% of cohort 2 patients in the primary trial suffered Dose Limiting Toxicities."}
{"id": "5c1e360c-fd93-4dd4-b855-71ba416d34cb", "result": " Entailment.\n\nThe text states that \"Able to swallow an oral medication.\" in the primary trial inclusion criteria. This means that patients must be able to receive medication orally to participate in the primary trial."}
{"id": "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d", "result": " Contradiction.\n\nThe text does not provide information about the types of adverse events reported in the primary trial and the secondary trial."}
{"id": "48f516ff-abb4-4312-9b00-02f53fb16218", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 32\" and \"26\" in the primary trial results 1. This means that under a third of the primary trial patients in the intervention arm experienced Pathologic Complete Response."}
{"id": "978d19fc-e7f6-485e-b8bd-cfcde06441ab", "result": " Entailment.\n\nThe text states that \"Histologically confirmed stage I, II, or III breast cancer\" and \"T1-3, N0-2, M0\" in the primary trial eligibility criteria. This means that T1 N0 M0 patients are eligible for the primary trial."}
{"id": "0a6d1b4c-244e-44e2-a229-62e4cbdfa979", "result": " Entailment.\n\nThe text states that \"The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks.\" in the primary trial results and \"Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment.\" in the secondary trial results. This means that the results of the secondary trial and the primary trial are non-comparable."}
{"id": "9bcc31df-c1f6-4785-9235-f673213acf3a", "result": " Entailment.\n\nThe text states that \"Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles).\" in both intervention 1 and 2 of the primary trial. This means that both the primary trial cohorts receive identical doses of Docetaxel."}
{"id": "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9", "result": " Contradiction.\n\nThe text states that \"Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week\" in intervention 1 of the primary trial. This means that the multivitamin arm + calcitriol arm cohort are required to receive oral medication as part of the intervention."}
{"id": "75cf4ec2-9f2b-4d5b-8772-af247eaca07b", "result": " Entailment.\n\nThe text states that \"Metastatic (stage IV) disease\" in the primary trial eligibility criteria. This means that patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial."}
{"id": "553f00ea-5197-4233-b1e0-e5727856b599", "result": " Contradiction.\n\nThe text states that \"Diarrhea [2]1/30 (3.33%)\" in the primary trial adverse events 1. This means that bowel-related adverse events were recorded in the primary trial."}
{"id": "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32", "result": " Contradiction.\n\nThe text does not provide information about mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS in the primary trial."}
{"id": "215a5c4a-d90c-4500-8284-0679ce311734", "result": " Entailment.\n\nThe text states that \"ErbB2(HER2)overexpressing breast cancer.\" in the primary trial inclusion criteria. This means that patients must have HER2- breast cancer to participate in the primary trial."}
{"id": "e9a4bd91-f58b-4234-9037-75e0699d1bbd", "result": " Entailment.\n\nThe text states that \"Study drug 190 mg/m^2 for 2 to 4 weeks.\" in intervention 1 of the primary trial. This means that the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate."}
{"id": "7d52734c-0801-413d-9ae2-d190b972cde5", "result": " Contradiction.\n\nThe text does not provide information about how to change the units from days to months."}
{"id": "5de9caeb-9dd5-4535-8fe3-289450d9c626", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 251\" and \"8\" in the primary trial results 1, and \"Overall Number of Participants Analyzed: 250\" and \"12\" in the primary trial results 2. This means that the Lapatinib Plus Capecitabine group had a higher percentage of patients with CNS Metastases than the Trastuzumab Plus Capecitabine group."}
{"id": "bebfc78e-b35f-4677-8342-9567a7e795a1", "result": " Entailment.\n\nThe text states that \"Diarrhea 0/92 (0.00%)\" in the secondary trial adverse events 1 and \"Diarrhea 1/93 (1.08%)\" in the secondary trial adverse events 2. This means that there is one case of Diarrhea in the secondary trial and none in the primary trial."}
{"id": "faa65e54-aa04-4595-8dae-05cf00b4c887", "result": " Contradiction.\n\nThe text states that \"Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles\" in intervention 1 of the primary trial. This means that both cohort 1 and cohort 2 patients of the primary trial are administered Ipatasertib."}
{"id": "751fd763-89fa-4d52-8bda-f09b490a5e78", "result": " Contradiction.\n\nThe text states that \"Number of patients event-free\" in the primary trial results. This means that there were recorded deaths in the primary trial cohorts."}
{"id": "c40fdf91-9f81-454a-bba9-ec5c950cef6e", "result": " Entailment.\n\nThe text states that \"Participants received matching placebo orally once daily.\" in intervention 2 of the primary trial. This means that one patient cohort in the primary trial received a placebo intervention."}
{"id": "31105b43-832b-48bc-a78d-ee90c155ca44", "result": " Contradiction.\n\nThe text states that \"Presence of hot flashes for 30 days prior to study registration\" in the primary trial eligibility, but does not mention this requirement in the secondary trial eligibility. This means that presence of hot flashes for 30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial."}
{"id": "49ba06b2-576d-4db2-80b6-51673416f2ba", "result": " Contradiction.\n\nThe text states that \"Percent Change in Net Influx Constant (Ki) by FLT PET\" in the primary trial results, but does not mention this outcome measurement in the secondary trial results. This means that the primary trial and the secondary trial do not measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts."}
{"id": "3cb71095-8e01-40dc-bbf5-eeffed55f354", "result": " Entailment.\n\nThe text states that \"Metastatic (stage IV) disease\" in the primary trial eligibility criteria. This means that patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial."}
{"id": "09fc4356-6154-427e-b710-ed5df6470aff", "result": " Contradiction.\n\nThe text states that \"Eye disorders: Keratitis: 0\" in the primary trial results 2. This means that 0% of cohort 2 patients in the primary trial suffered Keratitis."}
{"id": "446f3c69-0de5-475c-a8e2-ff40ece90672", "result": " Entailment.\n\nThe text states that \"HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies\" in the primary trial eligibility criteria. This means that only patients with HER2+ve breast cancer are eligible for the primary trial."}
{"id": "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2", "result": " Entailment.\n\nThe text states that \"0 0.0%\" in the primary trial results 1 and results 2. This means that the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects."}
{"id": "f0e845f9-8991-45b5-a520-51e934756f7a", "result": " Entailment.\n\nThe text states that \"Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks\" in the primary trial intervention. This means that the primary trial intervention involves one drug taken orally. The text also states that \"Sentinel Lymph Node Biopsy\" in the secondary trial intervention. This means that the secondary trial intervention is based on a medical procedure."}
{"id": "a0065d58-e03b-4dd0-9c81-cbbf651a6d45", "result": " Contradiction.\n\nThe text states that \"For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+ or FISH/CISH negative) status\" in the primary trial eligibility criteria. This means that patients with HER2+ve breast cancer are not eligible for the primary trial. The text also states that \"ErbB2(HER2)overexpressing breast cancer\" in the secondary trial eligibility criteria. This means that patients with HER2+ve breast cancer are eligible for the secondary trial."}
{"id": "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41", "result": " Contradiction.\n\nThe text states that \"Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\" in the primary trial eligibility criteria. This means that ECOG score > 2 is not necessary to be eligible for the primary trial."}
{"id": "973f090a-8967-4d75-bb8e-6166c868337c", "result": " Contradiction.\n\nThe text states that \"Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses)\" in the primary trial intervention 1. This means that cohort 1 patients of the primary trial are administered Ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles. The text also states that \"Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses)\" in the primary trial intervention 2. This means that cohort 2 patients of the primary trial are administered placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles. Since the dose of Ipatasertib and Placebo is the same for both cohorts, it can be concluded that cohort 1 patients of the primary trial are not administered higher doses of Ipatasertib and Placebo than cohort 2 patients."}
{"id": "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2", "result": " Contradiction.\n\nThe text states that \"Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ\" in the primary trial eligibility criteria. This means that patients must have palpable invasive breast cancer or ductal carcinoma in situ to be included in the primary trial. The text does not mention that patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial."}
{"id": "1d1f57f8-85f7-448c-a4bb-15957da568fd", "result": " Entailment.\n\nThe text states that \"600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression\" in the primary trial intervention. This means that the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression."}
{"id": "9f7d476e-9db3-4c00-abe6-4c2f0160470a", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 32\" and \"26\" in the primary trial results 1. This means that 26/32 * 100 = 81.25% of the primary trial patients in the intervention arm experienced Pathologic Complete Response."}
{"id": "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d", "result": " Entailment.\n\nThe text states that \"Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles)\" in the primary trial intervention 1 and intervention 2. This means that both the primary trial cohorts receive identical doses of Docetaxel. The text also states that \"In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal\" in the primary trial intervention 1. This means that cohort 1 also receives 100 mg/m^2 of Placebo."}
{"id": "3adcc8fc-b76b-407a-a006-729a13f571fb", "result": " Contradiction.\n\nThe text states that \"Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\" in the primary trial intervention 1. This means that cohort 1 patients are diagnosed with Triple-negative breast cancer (TNBC). The text also states that \"Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\" in the primary trial intervention 2. This means that cohort 2 patients are diagnosed with Non-small cell lung cancer (NSCLC)."}
{"id": "68379456-775b-463b-bfdb-d8aa42c9124b", "result": " Entailment.\n\nThe text states that \"Females with histologic or cytologic diagnosis of advanced breast cancer\" in the primary trial eligibility criteria. This means that patients must be female and have confirmed advanced breast cancer to be eligible for the primary trial. The text also states that \"Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\" in the secondary trial eligibility criteria. This means that patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial."}
{"id": "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb", "result": " Contradiction.\n\nThe text states that \"No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago\" in the primary trial eligibility criteria. This means that women currently undergoing endocrine therapy are excluded from the primary trial. The text does not mention that women currently undergoing endocrine therapy are excluded from the secondary trial."}
{"id": "f04d9695-81b8-4d70-877b-59caddf901bd", "result": " Entailment.\n\nThe text states that \"Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)\" in the secondary trial adverse events 1. This means that there was 1 case of Dyspnea in cohort 1 of the secondary trial. The text also states that \"Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)\" in the secondary trial adverse events 2. This means that there was 0 case of Dyspnea in cohort 2 of the secondary trial. The text also states that \"Total: 0/34 (0.00%)\" in the primary trial adverse events 1. This means that there was 0 case of Dyspnea in the primary trial."}
{"id": "f42e1874-343a-43ed-bb0c-884509c4793c", "result": " Contradiction.\n\nThe text states that \"Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])\" in the primary trial results. This means that the primary trial measures the Percentage of Participants With Objective Response. The text also states that \"Outcome Measurement: Progression Free Survival\" in the secondary trial results. This means that the secondary trial measures Progression Free Survival."}
{"id": "30483d7e-7703-459c-bd10-e2bd259c2a4f", "result": " Entailment.\n\nThe text states that \"Thrombocytopenia * 0/65 (0.00%)\" and \"Nausea * 0/65 (0.00%)\" in the primary trial adverse events 1. This means that there were 0 cases of Thrombocytopenia and Nausea in cohort 1 of the primary trial."}
{"id": "7cde9a22-a91f-4feb-892d-7cbd35f96a27", "result": " Entailment.\n\nThe text states that \"Outcome Measurement: Change in Tumor Size (CTS) From Baseline to the End of Cycle 2\" in the primary trial results. This means that the primary trial reports the changes in tumor size for patients in its cohorts."}
{"id": "16c29502-4683-4087-9410-ff1b786556f5", "result": " Contradiction.\n\nThe text states that \"Constipation 1/41 (2.44%)\" in the primary trial adverse events 1. This means that there was 1 case of Constipation in the primary trial. The text also states that \"Skin infection 2/41 (4.88%)\" in the primary trial adverse events 1. This means that there were 2 cases of Skin infection in the primary trial."}
{"id": "5c975af8-6b7f-4a5d-b4a6-257c76763ce9", "result": " Entailment.\n\nThe text states that \"Acute myocardial infarction 0/199 (0.00%)\" in the secondary trial adverse events 1. This means that there were 0 cases of Acute myocardial infarction in the entire patient cohort of the primary trial. The text also states that \"Cardiopulmonary failure 1/199 (0.50%)\" and \"Supraventricular tachycardia 0/199 (0.00%)\" in the secondary trial adverse events 1. This means that there were 1 case of Cardiopulmonary failure and 0 cases of Supraventricular tachycardia in the entire patient cohort of the primary trial. The text also states that \"Acute myocardial infarction 1/36 (2.78%)\" in the secondary trial adverse events 2. This means that there was 1 case of Acute myocardial infarction in cohort 1 of the secondary trial. The text also states that \"Cardiopulmonary failure 0/36 (0.00%)\" and \"Supraventricular tachycardia 1/36 (2.78%)\" in the secondary trial adverse events 2. This means that there were 0 cases of Cardiopulmonary failure and 1 case of Supraventricular tachycardia in cohort 1 of the secondary trial."}
{"id": "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7", "result": " Contradiction.\n\nThe text states that \"Total: 13/61 (21.31%)\" in the primary trial adverse events 1. This means that there were 13 total AEs in cohort 1 of the primary trial. The text also states that \"Total: 12/60 (20.00%)\" in the primary trial adverse events 2. This means that there were 12 total AEs in cohort 2 of the primary trial."}
{"id": "8e91e404-086e-4063-8d54-83d1b8ebd969", "result": " Entailment.\n\nThe text states that \"Total: 6\" in the primary trial adverse events 1. This means that there were 6 total AEs in cohort 1 of the primary trial. The text also states that \"Atrial fibrillation 1/67 (1.49%)\" in the primary trial adverse events 1. This means that there was 1 case of Atrial fibrillation in cohort 1 of the primary trial. Therefore, over 1/6 patients in cohort 1 of the primary trial suffered adverse events."}
{"id": "b8322b23-a4f6-4cba-9761-be826b509de7", "result": " Entailment.\n\nThe text states that \"Total: 0/150 (0.00%)\" in the primary trial adverse events 1. This means that there were 0 cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the primary trial. The text also states that \"Total: 14/41 (34.15%)\" in the secondary trial adverse events 1. This means that there were 14 cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial."}
{"id": "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3", "result": " Entailment.\n\nThe text states that \"Total: 0/92 (0.00%)\" in the secondary trial adverse events 1. This means that there is only one case of Diarrhea in the secondary trial. The text also states that \"Total: 59/373 (15.82%)\" and \"Total: 69/377 (18.30%)\" in the primary trial adverse events 1 and 2. This means that there are over 14 different types of AEs recorded in the primary trial cohorts."}
{"id": "4b97a844-8d52-48bb-8eda-ca205268f016", "result": " Contradiction.\n\nThe text states that \"Life expectancy 1 year\" in the primary trial eligibility. This means that patients must have a Life expectancy of 1 year to enroll in the primary trial."}
{"id": "2a03c17f-3afe-40f1-a0db-4b876ee8c700", "result": " Entailment.\n\nThe text states that \"Outcome Measurement: Percent Change in Net Influx Constant (Ki) by FLT PET\" in the primary trial results. This means that the primary trial measures the Percent Change in Net Influx Constant (Ki) by FLT PET. The text also states that \"Outcome Measurement: Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\" in the secondary trial results. This means that the secondary trial measures Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)."}
{"id": "3ba42f68-a643-4d10-afd0-cbb358d05a6f", "result": " Contradiction.\n\nThe text does not provide any information about the doses of Paclitaxel used in the primary and secondary trials."}
{"id": "0a079cca-abde-42cf-9cec-a76e7a380e14", "result": " Entailment.\n\nThe text does not mention anything about surgery as part of the intervention in either of the cohorts in the primary trial."}
{"id": "9c033072-5f94-4d79-af47-126d531f0d6e", "result": " Contradiction.\n\nThe text does not mention anything about Holocraneal cephale and Catheter - related infections in either the primary or secondary trial."}
{"id": "a52b2d4f-0b06-4960-a9c3-88cb92df0980", "result": " Contradiction.\n\nThe text states that \"Lapatinib was orally administered at 1250 milligrams (mg) once daily\" and \"Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle\". This means that the primary trial participants receive Capecitabine twice daily for 14 days out of every 21-day cycle, while they receive Lapatinib once daily for the entire 21-day cycle. Therefore, the primary trial participants receive Capecitabine more often than they receive Lapatinib."}
{"id": "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb", "result": " Contradiction.\n\nThe text states that \"women >=18 years of age\" in the primary trial eligibility. This means that only women who are 18 years of age or older can be eligible for the primary trial. Alex is a 32 year old man, so he cannot be eligible for the primary trial."}
{"id": "1842904b-5371-49ee-b6f4-8831b879098b", "result": " Entailment.\n\nThe text states that \"Total: 11/56 (19.64%)\" in the primary trial adverse events 1. This means that there were 11 total adverse events in the primary trial. The text also states that \"Febrile Neutropenia * 3/56 (5.36%)\" in the primary trial adverse events 1. This means that there were 3 cases of Febrile Neutropenia in the primary trial. Since there were 11 total adverse events, and 3 of them were Febrile Neutropenia, this means that Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients."}
{"id": "324562e6-2b61-4a07-b937-86f99689f2d5", "result": " Entailment.\n\nThe text states that \"Total: 17/65 (26.15%)\" in the primary trial adverse events 1. This means that there were 17 total adverse events in the primary trial. The text also states that \"Diarrhoea 5/65 (7.69%)\" in the primary trial adverse events 1. This means that there were 5 cases of Diarrhoea in the primary trial. The text also states that \"Total: 173/472 (36.65%)\" in the secondary trial adverse events 1. This means that there were 173 total adverse events in the secondary trial. The text also states that \"Anaemia 6/472 (1.27%)\" in the secondary trial adverse events 1. This means that there were 6 cases of Anaemia in the secondary trial. Since there were 17 total adverse events in the primary trial, and 5 of them were Diarrhoea, this means that Diarrhoea was the most common adverse event in the primary trial. Since there were 173 total adverse events in the secondary trial, and 6 of them were Anaemia, this means that Anaemia was the most common adverse event in the secondary trial."}
{"id": "74e376d7-5713-43f3-93f1-9608059c9547", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 42\" and \"Measure Type: Number\nUnit of Measure: percentage of patients 28 (16 to 42)\" in the primary trial results 1. This means that 28 out of 42 patients (or 66.67%) experienced an Objective Benefit from the Liposomal Doxorubicin intervention. The text also states that \"Overall Number of Participants Analyzed: 44\" and \"Measure Type: Number\nUnit of Measure: percentage of patients 31 (18 to 45)\" in the primary trial results 2. This means that 31 out of 44 patients (or 70.45%) experienced an Objective Benefit from the Docetaxel Then Liposomal Doxorubicin intervention. Therefore, both of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients. The text does not mention anything about fatal complications in the Docetaxel Then Liposomal Doxorubicin intervention."}
{"id": "0e609fad-9a28-4fb6-90b6-32a731e3b02c", "result": " Entailment.\n\nThe text states that \"Measure Type: Number\nUnit of Measure: percentage of participants 26 (13 to 44)\" in the primary trial results 1. This means that the primary trial reports its results as percentages. The text also states that \"Measure Type: Number\nUnit of Measure: proportion of nodes Proportion of SNs (PTc) detected by Tc method: 0.86\nProportion of SNs (PICG) detected by ICG method: 0.95\" in the secondary trial results 1. This means that the secondary trial reports its results as proportions."}
{"id": "236780db-9e59-4dc9-8da0-e786287011cf", "result": " Contradiction.\n\nThe text states that \"Pemetrexed\n600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression\". This means that the primary trial intervention protocol lasts for 14 days, then there is a 14 day break, then another 14 day treatment, and so on."}
{"id": "6d621974-c719-46df-8a50-d94e49583e33", "result": " Contradiction.\n\nThe text states that \"Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization\" in the primary trial eligibility. This means that patients who have undergone Prior treatment for breast cancer with endocrine therapy are allowed to participate in the primary trial, but they must discontinue this treatment at randomization."}
{"id": "a9907a2e-254a-45ca-af50-3e44fd2f7af3", "result": " Entailment.\n\nThe text states that \"Total: 3/39 (7.69%)\" in the primary trial adverse events 1. This means that there were 3 total adverse events in the first cohort of the primary trial. The text also states that \"Neutropenia 1/39 (2.56%)\" in the primary trial adverse events 1. This means that there was 1 case of Neutropenia in the first cohort of the primary trial. The text also states that \"Total: 3/21 (14.29%)\" in the primary trial adverse events 2. This means that there were 3 total adverse events in the second cohort of the primary trial. The text also states that \"Neutropenia 1/21 (4.76%)\" in the primary trial adverse events 2. This means that there was 1 case of Neutropenia in the second cohort of the primary trial."}
{"id": "40f699a1-fbc6-40de-8e80-85b28f71632f", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 70\" and \"Measure Type: Count of Participants\nUnit of Measure: Participants Grade 1: 53 75.7%\nGrade 2: 40 57.1%\nGrade 3: 18 25.7%\nGrade 4: 2 2.9%\nGrade 5: 12 17.1%\". This means that 53 patients experienced a grade 1 adverse event, 40 patients experienced a grade 2 adverse event, 18 patients experienced a grade 3 adverse event, 2 patients experienced a grade 4 adverse event, and 12 patients experienced a grade 5 adverse event. Therefore, the most common severity was grade 1, and the least common severity was grade 4."}
{"id": "6499b181-7a23-4073-8459-ad46ff02b20f", "result": " Contradiction.\n\nThe text states that \"Each treatment cycle is 28 days\". This means that the participants of the primary trial will receive the intervention for a total of 28 days, not 12 cycles (28 days)."}
{"id": "2da13cd4-7189-4f85-be4d-5c1e213ae293", "result": " Contradiction.\n\nThe text states that \"Total: 13/61 (21.31%)\" in the primary trial adverse events 1. This means that there were 13 total adverse events in the first cohort of the primary trial. The text also states that \"Non-cardiac chest pain 2/61 (3.28%)\" in the primary trial adverse events 1. This means that there were 2 cases of Non-cardiac chest pain in the first cohort of the primary trial. Therefore, the most common AE in the primary trial was not Non-cardiac chest pain."}
{"id": "a9bb6de9-c6f8-4c99-81cd-f101cbaab387", "result": " Contradiction.\n\nThe text states that \"Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain\". This means that patients must have radiographically confirmed metastases to the brain in order to be eligible for the primary trial."}
{"id": "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7", "result": " Entailment.\n\nThe text states that \"Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.\nA patient has clinical benefit from treatment if CR + PR + SD > 24 weeks\". This means that a patient has clinical benefit from treatment if they achieve either CR, PR, or SD for more than 24 weeks. The text also states that \"Overall Number of Participants Analyzed: 35\nMeasure Type: Number\nUnit of Measure: participants 35\". This means that all 35 patients in the primary trial achieved clinical benefit from treatment."}
{"id": "016943fa-57ea-4293-8131-03292ea1836c", "result": " Entailment.\n\nThe text states that \"Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria\". This means that patients with operable, node-positive or high-risk node-negative HER2-positive breast carcinoma are eligible for the primary trial. The text also states that \"Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics:\nnode-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR\nnode-negative AND at least one of the following features:\nTumor >2 cm or\nTumor >1 cm and\nNegative estrogen receptor/progesterone receptor (ER/PR) or\nMalignancy Grade 2-3 or\nPresence of peritumoral vascular invasion or\nAge <35 years\". This means that patients with a node positive T2 N2 M0 adenocarcinoma of the breast, or a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm, would be eligible for the primary trial."}
{"id": "402f0dbf-cf67-4425-b300-a0a3df4d59d3", "result": " Entailment.\n\nThe text states that \"Outcome Measurement:\nObjective Response Rate (ORR)\" in the primary trial results 1. This means that the primary trial uses Objective Response Rate as the outcome measurement for its intervention. The text also states that \"Outcome Measurement:\nObjective Response (OR)\" in the secondary trial results 1. This means that the secondary trial uses Objective Response as the outcome measurement for its intervention."}
{"id": "62be4676-099f-4c42-8029-773af8fde6f7", "result": " Contradiction.\n\nThe text states that \"Able to lie still for 1.5 hours for PET scanning\". This means that patients must be able to lie still for 1.5 hours for PET scanning in order to participate in the primary trial."}
{"id": "1180dd58-61b8-4c48-ab00-7d458e68c85b", "result": " Contradiction.\n\nThe text states that \"Outcome Measurement:\nSafety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks\nThe safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI.\nGrade 3 or 4 skin/subcutaneous or pulmonary toxicity.\nThe development of clinical fat necrosis.\nThe development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically.\" in the primary trial results 1. This means that the primary trial outcome measurement is the safety of external-beam PBI utilizing 40Gy in ten daily fractions over two weeks. The text also states that \"Outcome Measurement:\nOverall Tumor Response\nBest response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment.\" in the secondary trial results 1. This means that the secondary trial outcome measurement is the overall tumor response."}
{"id": "566bdc2d-7c4a-4547-87da-ac81447ecca8", "result": " Contradiction.\n\nThe text states that \"Overall Number of Participants Analyzed: 251\nMeasure Type: Number\nUnit of Measure: participants 8\" in the primary trial results 1. This means that there were 8 participants in the Lapatinib Plus Capecitabine group who had CNS metastases as the site of first relapse. The text also states that \"Overall Number of Participants Analyzed: 250\nMeasure Type: Number\nUnit of Measure: participants 12\" in the primary trial results 2. This means that there were 12 participants in the Trastuzumab Plus Capecitabine group who had CNS metastases as the site of first relapse. Therefore, the Trastuzumab Plus Capecitabine group did not have a higher percentage of patients with CNS metastases as the site of first relapse than the Lapatinib Plus Capecitabine group."}
{"id": "d310ec4e-993e-4827-8dc5-9aca053972db", "result": " Entailment.\n\nThe text states that \"Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks\" in the primary trial intervention 1. This means that the primary trial intervention involves one drug taken orally. The text also states that \"Sentinel Lymph Node Biopsy\" in the secondary trial intervention 1. This means that the secondary trial intervention is based on a medical procedure."}
{"id": "a5617ae4-05a3-42d0-9e14-141de5f8c010", "result": " Entailment.\n\nThe text states that \"Conjunctivitis 0/519 (0.00%)\" in the secondary trial adverse events 1. This means that there were 0 cases of Conjunctivitis in the secondary trial. The text also states that \"Total: 16/48 (33.33%)\" in the primary trial adverse events 1. This means that there were 16 total adverse events in the first cohort of the primary trial. The text does not mention any cases of Conjunctivitis in the primary trial. Therefore, the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any."}
{"id": "42d1fcd3-8faa-4065-bbba-42cc90ab67fb", "result": " Entailment.\n\nThe text states that \"Outcome Measurement:\nNumber of Patients With Pathological Complete Response Rate\" in the primary trial results 1. This means that the primary trial measures the pCR of their patient cohort. The text also states that \"Outcome Measurement:\nDisease Free Survival.\" in the secondary trial results 1. This means that the secondary trial does not measure the pCR of their patient cohort."}
{"id": "d01fda83-5dc8-4ad5-92b8-7553dabd7046", "result": " Contradiction.\n\nThe text states that \"Outcome Measurement:\nProgression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.\" in the primary trial results 1. This means that the outcome measurement of the primary trial is progression-free survival (PFS). PFS is defined as the length of time during and after the treatment, that a patient lives with the disease but it does not get worse."}
{"id": "985bc5a0-bc21-447f-92f1-150e23ede3f5", "result": " Contradiction.\n\nThe text states that \"Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.\" in the primary trial results 1. This means that a patient has a partial response if they have a >=30% decrease in the sum of the longest diameter of target lesions. The text also states that \"Overall Number of Participants Analyzed: 35\" in the primary trial results 1. This means that there were 35 patients in the primary trial. Therefore, not all of the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions."}
